Physiological restraint of Bak by Bcl-xL is essential for cell survival

Genes and Development

Volumn 30, Issue 10, 2016, Pages 1240-1250

  Lee, Erinna F ^a,b,c,d   Grabow, Stephanie ^a,b   Chappaz, Stephane ^a,b   Dewson, Grant ^a,b   Hockings, Colin ^a,b   Kluck, Ruth M ^a,b   Debrincat, Marlyse A ^a,b   Gray, Daniel H ^a,b   Witkowski, Matthew T ^a,b   Evangelista, Marco ^c,d   Pettikiriarachchi, Anne ^a   Bouillet, Philippe ^a,b   Lane, Rachael M ^a   Czabotar, Peter E ^a,b   Colman, Peter M ^a,b   Smith, Brian J ^c   Kile, Benjamin T ^a,b   Fairlie, W Douglas ^a,b,c,d  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

Author keywords

Apoptosis; Bak; Bcl 2; Bcl xL; BH3

Indexed keywords

GLYCINE; LEUCINE; PROTEIN BAK; PROTEIN BCL XL; ANTINEOPLASTIC AGENT; PROTEIN BCL X; PROTEIN BINDING;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HYDROGEN BOND; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STRUCTURE; T LYMPHOCYTE; THROMBOCYTE LIFESPAN; ANIMAL; C57BL MOUSE; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; THROMBOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; BLOOD PLATELETS; CELL LINE; CELL SURVIVAL; HUMANS; MICE; MICE, INBRED C57BL; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAINS; T-LYMPHOCYTES;

EID: 84969900687     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.279414.116     Document Type: Article

References (43)

1. Banerjee A, Grumont R, Gugasyan R, White C, Strasser A, Gerondakis S. 2008. NF-κB1 and c-Rel cooperate to promote the survival of TLR4-activated B cells by neutralizing Bim via distinct mechanisms. Blood 112: 5063-5073.
2. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM, Strasser A. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286: 1735-1738.
3. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. 2006. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365.
4. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. 2005. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
5. Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D, Kim H, Takeda S, Reyna DE, Chan PM, et al. 2015. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat Cell Biol 17: 1270-1281.
6. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, Korsmeyer SJ. 2001. BCL-2, BCL-XL sequester BH3 domainonly molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8: 705-711.
7. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ. 2003. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 301: 513-517.
8. Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD, Lee EF, Yao S, Robin AY, Smith BJ, et al. 2013. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152: 519-531.
9. Dai H, Ding H, Meng XW, Peterson KL, Schneider PA, Karp JE, Kaufmann SH. 2015. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes Dev 29: 2140-2152.
10. Dewson G, Kratina T, Sim HW, Puthalakath H, Adams JM, Colman PM, Kluck RM. 2008. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol Cell 30: 369-380.
11. Emsley P, Cowtan K. 2004. COOT: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132.
12. Fairlie WD, Uboldi AD, Hemmings GJ, Smith BJ, Martin HM, Morgan PO, Baca M. 2003. A family of leukemia inhibitory factor-binding peptides that can act as antagonists when conjugated to poly(ethylene glycol). Biochemistry 42: 13193-13201.
13. Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, Huang DC, Adams JM. 2008. Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci 105: 18081-18087.
14. Hockings C, Anwari K, Ninnis RL, Brouwer J, O’Hely M, Evangelista M, Hinds MG, Czabotar PE, Lee EF, Fairlie WD, et al. 2015. Bid chimeras indicate that most BH3-only proteins can directly activate Bak and Bax, and show no preference for Bak versus Bax. Cell Death Dis 6: e1735.
15. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, et al. 2011. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 208: 2017-2031.
16. Josefsson EC, White MJ, Dowling MR, Kile BT. 2012. Platelet life span and apoptosis. Methods Mol Biol 788: 59-71.
17. Kabsch W. 2010. Xds. Acta Crystallogr D Biol Crystallogr 66: 125-132.
18. Kluck RM, Esposti MD, Perkins G, Renken C, Kuwana T, Bossy-Wetzel E, Goldberg M, Allen T, Barber MJ, Green DR, et al. 1999. The pro-apoptotic proteins, Bid and Bax, cause a limited permeabilization of the mitochondrial outer membrane that is enhanced by cytosol. J Cell Biol 147: 809-822.
19. Kodama T, Takehara T, Hikita H, Shimizu S, Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Tadokoro S, et al. 2010. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 138: 2487-2498.
20. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD. 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17: 525-535.
21. Lazarou M, Stojanovski D, Frazier AE, Kotevski A, Dewson G, Craigen WJ, Kluck RM, Vaux DL, Ryan MT. 2010. Inhibition of Bak activation by VDAC2 is dependent on the Bak transmembrane anchor. J Biol Chem 285: 36876-36883.
22. Leber B, Lin J, Andrews DW. 2010. Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene 29: 5221-5230.
23. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD. 2007. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14: 1711-1713.
24. Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN, Puthalakath H, Bouillet P, Colman PM, Huang DC, et al. 2008. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol 180: 341-355.
25. Lee EF, Sadowsky JD, Smith BJ, Czabotar PE, Peterson-Kaufman KJ, Colman PM, Gellman SH, Fairlie WD. 2009. High-resolution structural characterization of a helical α/β-peptide foldamer bound to the anti-apoptotic protein Bcl-xL. Angew Chem Int Ed Engl 48: 4318-4322.
26. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192.
27. Liu X, Zhu Y, Dai S, White J, Peyerl F, Kappler JW, Marrack P. 2006. Bcl-xl does not have to bind Bax to protect T cells from death. J Exp Med 203: 2953-2961.
28. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP, Green DR. 2011. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 44: 517-531.
29. Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW, Thompson CB. 1995. Bclx regulates the survival of doublepositive thymocytes. Proc Natl Acad Sci 92: 4763-4767.
30. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, et al. 2007. Programmed anuclear cell death delimits platelet life span. Cell 128: 1173-1186.
31. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ. 2005. Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61: 458-464.
32. Merino D, Giam M, Hughes PD, Siggs OM, Heger K, O’Reilly LA, Adams JM, Strasser A, Lee EF, Fairlie WD, et al. 2009. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 186: 355-362.
33. Moldoveanu T, Liu Q, Tocilj A, Watson M, Shore G, Gehring K. 2006. The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol Cell 24: 677-688.
34. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, et al. 1995. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267: 1506-1510.
35. Oberstein A, Jeffrey PD, Shi Y. 2007. Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J Biol Chem 282: 13123-13132.
36. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307-326.
37. Uren RT, Dewson G, Bonzon C, Lithgow T, Newmeyer DD, Kluck RM. 2005. Mitochondrial release of pro-apoptotic proteins: electrostatic interactions can hold cytochrome c but not Smac/DIABLO to mitochondrial membranes. J Biol Chem 280: 2266-2274.
38. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. 2012. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151: 344-355.
39. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. 2005. Proapoptotic Bak is sequestered by Mcl- 1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
40. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, et al. 2007. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
41. Wilson WH, O’Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, et al. 2010. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11: 1149-1159.
42. Youle RJ, Strasser A. 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
43. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, et al. 2007. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14: 943-951.